An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

• Published in: Renal replacement therapy 2022-06, Vol.8 (1), p.1-10, Article 26
• Main Authors: Ugamura, Daisuke, Hosojima, Michihiro, Kabasawa, Hideyuki, Tanabe, Naohito, Yoshizawa, Yuta, Suzuki, Yoshiki, Saito, Akihiko, Narita, Ichiei
• Format: Article
• Language: English
• Subjects: Dulaglutide; Glucagon-like peptide-1 receptor agonist; Hemodialysis; Once-weekly; Type 2 diabetes mellitus
• ISSN: 2059-1381; 2059-1381
• DOI: 10.1186/s41100-022-00409-4

Abstract Background Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM). However, the efficacy and safety of dulaglutide remain unclear in insulin-treated patients with T2DM on maintenance hemodialysis (HD). Methods Dulaglutide treatment was initiated, and the insulin dose was adjusted according to the needs of individual participants. Primary outcomes were changes in the mean and standard deviation (SD) of blood glucose (BG) levels and mean amplitude of glycemic excursions (MAGE) evaluated by continuous glucose monitoring (CGM) for six days, glycated albumin (GA), glycated hemoglobin (HbA1c), pre-dialysis blood glucose levels, and daily total insulin dose from the baseline over 24 weeks. Secondary outcomes were changes in treatment satisfaction and QOL levels from the baseline, measured by using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Diabetes Therapy-Related Quality of Life questionnaire (DTR-QOL) scores. Results The analysis was performed on the 12 participants who completed the study. The GA level (median − 1.8 [interquartile range − 6.6, − 0.3] %; p = 0.026) and daily total insulin dose (− 15.0 [− 24.5, − 9.4] U/day; p = 0.002) significantly decreased without increasing hypoglycemia (area over the glucose curve